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Background/aim: Previously we showed that Fms-like tyrosine kinase (FLT3) changes its cellular localization upon partial hepatectomy,
suggesting a role in liver regeneration. FLT3 was also shown to play an important function in cellular proliferation and activation of
PI3K and Ras. Thus, we aimed to investigate the role of FLT3 in hepatocellular tumorigenesis utilizing in vitro and in vivo models.
Materials and methods: We used Snu398 cells that express FLT3. We investigated these cells’ in vitro proliferation and invasion abilities
by treatment with the FLT3 inhibitor K-252a or by knocking-down with FLT3 shRNA,. Furthermore, the effect of blocking FLT3 activity
and expression during in vivo tumorigenesis was assessed with xenograft models.
Results: After K-252a treatment or stable knock-down, these cells’ proliferation and migration abilities were highly diminished in vitro.
In addition, significant diminution in tumorigenicity of Snu398 cells was also obtained in vivo. When FLT3 knocked-down Snu398 cells
were injected into nude mice, we did not detect αSMA expression in these tumors, suggesting a role for FLT3 in in vivo invasiveness.
Conclusion: Our data provided evidence that FLT3 has a crucial role both in hepatocarcinogenesis and its invasiveness. Therefore,
targeting FLT3 and/or its activity may be a promising tool for combating hepatocellular carcinomas.
Key words: Fms-like tyrosine kinase, liver cancer, regeneration, invasiveness, tyrosine kinase

1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most
common neoplasm worldwide (1) and the third leading
cause of cancer-induced death following lung and stomach
cancers due to the lack of targeted therapies and resistance
to chemotherapeutic agents (2). There is strong evidence
that shows a link between the disease and risk factors such
as HBV, HCV infection, aflatoxins, and excessive alcohol
consumption (3).
Fms-like tyrosine kinase (FLT3) is a type III receptor
tyrosine kinase (RTK) and a hematopoietic lineage marker
(4). FLT3 signaling was shown to play an important role
in the stimulation of myeloid and lymphoid progenitor
cell proliferation (4). Signaling molecules such as PI3K
and Ras were activated when FLT3 bound to FLT3
ligand (FLT3L) (5). Upon ligand binding, FLT3 changes
conformation and forms a homodimer, which brings the
kinase domains in close proximity for phosphorylation.
After dimerization, downstream signaling is initiated,
followed by internalization and subsequent degradation of
* Correspondence: akcali@ankara.edu.tr
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the complex. These processes happen very quickly where
the first degraded products of the FLT3L-FLT3 complex
are seen within 20 min after stimulation (6).
FLT3 signaling pathways participate in many
physiological processes throughout embryogenesis and
development. FLT3 is crucial for hematopoietic cell
development, and aberrancy in the functioning of FLT3
was demonstrated to cause different leukemia types
(7). In addition to its role in stimulating myeloid and
lymphoid progenitor cell proliferation and as an indicator
of hematopoietic lineage, FLT3 is also a marker of hepatic
bipotential progenitor cells or oval cells in rodents (8,9).
We previously demonstrated that FLT3 is activated
during liver regeneration in rats, suggesting that FLT3
may contribute to the proliferation of hepatocytes (10).
Since the fetal liver is the primary site for hematopoiesis
during early development, a close relationship between the
hematopoietic cells and the hepatic parenchyma can easily
be drawn (11). Signals between the hematopoietic cells
within the fetal liver and the hepatocytes are crucial for the
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development of both cell types. Oncostatin M secreted from
hematopoietic cells induces hepatocyte differentiation via
increased HNF4α expression, and the coculture of fetal
hepatocytes with hematopoietic cells showed increased
growth and proliferation of hematopoietic cells (12).
Since FLT3 participates in liver regeneration (10)
and cellular proliferation (13,14), and there is a close
relationship between fetal liver and hematopoiesis
(15,16), we hypothesized that FLT3 may have a role in
hepatocellular tumorigenesis and the FLT3 expressing
HCC line would be an appropriate tool to test its role. We
tested our idea with both in vitro and in vivo models after
knocking down FLT3 with specific shRNA or using the
specific kinase inhibitor K-252a.
2. Materials and methods
2.1. Cell culture
Huh7, Hep40, and SK-Hep-1 cells were cultured in DMEM
(HyClone, USA) supplemented with 10% FBS and 100 U/
mL penicillin-streptomycin. Snu398 cells were cultured in
RPMI1640 (HyClone) supplemented with 10% FBS, 100
U/mL penicillin-streptomycin, and 0.1 mM nonessential
amino acids (HyClone). Cells were incubated at 37 °C with
5% CO2 and media were changed every 3 days.

2.2. K-252a treatment of Snu398 cells
K-252a kinase inhibitor (Nocardiopsis sp.) (Calbiochem,
USA) was used at a final concentration of 200 nM 2 h prior
to experiments, as we used it in our previous studies (17).
The same volume of DMSO was used as a control.
2.3. Stable knock-down of FLT3 mRNA in Snu398 cells
FLT3 shRNA (Openbiosystems, USA) and GFP (Clontech
Laboratories, USA) plasmids were transfected using
X-tremeGENE HP DNA transfection reagent (Roche
Applied Science, Germany). Snu398 cells were seeded
on 6-well plates the day before transfection. First 1 µg of
plasmid, either shRNA containing or not, was used for each
well together with the X-tremeGENE HP DNA transfection
reagent. Before transfection, the X-tremeGENE HP DNA
transfection reagent and plasmid DNA were equilibrated
to 15 to 25 °C. FLT3 shRNA and GFP plasmids were
diluted to 1 µg plasmid DNA/100 µL medium (0.01 µg/
µL) at a 1:3 ratio using serum-free RPMI. Next, 2 µL of
X-tremeGENE HP DNA transfection reagent was added
into each 100 µL of plasmid DNA diluent and incubated at
room temperature for 15 min. Following incubation, the
mixture was added dropwise on the top of the cells and
left in the incubator for 48 h. The FLT3 mRNA expression
of the transfected cells was analyzed by performing RTPCR using half of the cells in each well. Upon observing
a decrease in the FLT3 expression in shRNA transfected,
but not in empty vector transfected cells, all cells that
underwent transfection were plated into two 75-cm2 flasks

separately in fresh RPMI containing puromycin (SigmaAldrich, USA) with 0.75 µg/mL final concentration. After
2 weeks, cells were harvested and diluted in puromycin
containing RPMI to seed one cell per each well of a 96well plate. In 2 to 3 weeks, plasmid containing cells were
expected to form colonies that either had decreased or
unchanged expression of FLT3.
2.4. Total RNA isolation and reverse transcription
Cells were trypsinized and total cellular RNA was isolated
from the precipitate by using the RNeasy mini kit (Qiagen,
Germany) according to the manufacturer’s protocol, with
additional DNase treatment. The cDNAs were synthesized
from the total RNA samples with the DyNAmo cDNA
synthesis kit (Finnzymes, Finland) according to the
manufacturer’s protocol. cDNA amplification for flt3
and gapdh was performed by using DyNAzyme II
(Finnzymes) with the following primers: human FLT3:
Forward 5’GGAAGAAGAGGAGGACTTA3’, Reverse
5’AGGTCTCTGTGAACACACGA3’; human GAPDH:
Forward
5’GGCTGAGAACGGGAAGCTTGTCAT3’;
Reverse 5’CAGCCTTCTCCATGGTGGTGAAGA3’. The
initial denaturation step was at 95 °C for 5 min, followed
by 30 cycles for flt3 and 23 cycles for gapdh of denaturation
for 30 s at 94 °C, annealing for 30 s at 60 °C, followed by
extension for 30 s at 72 °C. A final extension at 72 °C for 5
min was applied to all reactions.
2.5. Total protein isolation and Western blotting
Cells were scraped and the precipitate was treated with
a lysis buffer containing 0.05 M Tris-HCl, 1X protease
inhibitor, 0.25 M NaCl, and 1% (v/v) IGEPAL. Protein
concentration was determined with Bradford protein assay
(18). First 20 µg of the total protein was separated on 10%
SDS-PAGE and transferred to a polyvinylidene fluoride
membrane. After the membrane was blocked for 2 h at
room temperature, FLT3 and Calnexin primary antibodies
(1:1000) were applied overnight at 4 °C. Anti-rabbit-HRP
(1:1000) was applied for 1 h. Finally, Super Signal West
Femto maximum sensitivity substrate (Thermo Scientific,
USA) was used. All antibodies were purchased from Santa
Cruz (Santa Cruz Biotechnology Inc., USA).
2.6. Immunofluorescence staining for Snu398 cells
Cells were grown on coverslips and following methanol
fixation, blocking was performed at room temperature for 1
h. Anti-FLT3 antibody (Santa Cruz; 1:200) incubation was
done at room temperature for 1 h. Alexa Fluor 568-tagged
anti-rabbit IgG secondary antibody (Invitrogen, USA)
(1:1000) was used for another 1 h at room temperature.
Coverslips were mounted with UltraCruz mounting
medium with DAPI (Santa Cruz) for counter staining.
Slides were observed with a fluorescent microscope (Leica
TCS/SP5). The excitation wavelengths for Alexa Fluor 568
and DAPI were 578 nm and 359 nm, respectively.
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2.7. Immunofluorescence staining for frozen sections
The primary antibody of FLT3 (Santa Cruz) and αSMA
(Abcam) was applied to the cryo-sections (5 μm) of
tumor xenografts at a 1:200 concentration for 1 h at room
temperature. FITC-tagged anti-rabbit IgG secondary
antibody (Sigma-Aldrich) (1:200) was used for 1 h at
room temperature. Slides were mounted with UltraCruz
mounting medium with DAPI (Santa Cruz) for counter
staining and observed with a fluorescent microscope
(Leica TCS/SP5). The excitation wavelengths for FITC and
DAPI were 490 nm and 359 nm, respectively.
2.8. MTT assay
Cell proliferation Kit I (MTT) (Roche, Switzerland) was
used to check the proliferation characteristics of Snu398
cells upon K-252a treatment or FLT3 shRNA transfection.
Snu398 cells were either treated with K252-a or DMSO
2 h prior to the experiment. Next, 104 cells/well were
seeded into a 96-well plate and left at 37 °C for 24 h. FLT3
shRNA and empty vector transfected Snu398 cells were
seeded at a density of 5 × 103 cells/well and left at 37 °C
for 72 h. Subsequent labeling and solubilization steps were
performed according to the manufacturer’s protocol. OD
values at 551 nm were read with Synergy H1 microplate
reader (BioTek Instruments Inc., USA).
2.9. Wound healing assay
After cells reached 100% confluency on the 6-well plates,
3 vertical scratches were made. Cells were then incubated
either with 10% FBS or 2% FBS to induce serum starvation.
Wounds were monitored for 48 h and photos of the same
regions were taken in 24-h intervals. Healed wound
distance was measured by calculating the average of the
difference between the initial and final wound sizes of 10
separate areas.
2.10. Matrigel invasion assay
Matrigel Basement Membrane Matrix (BD Biosciences,
USA) was diluted, put into a 24-well transwell plate
(Corning Incorporated Life Sciences, USA), and incubated
at 37 °C for 4–5 h. Then 105 cells were put into each of the
Matrigel coated transwells. The lower chamber of each well
was filled with RPMI containing 5 µg/mL fibronectin and
left at 37 °C for 20–24 h. Invaded cells were stained with
Diff-Quick staining solution kit (IMEB Inc., California,
USA). Noninvaded cells were removed and the invaded
cells were counted under a light microscope.
2.11. Nude mice tumor xenografts
Each group contained 5 male CD1 nude mice. First 6 × 106
cells and their controls were injected subcutaneously to the
opposite sides of the animals. The animals were permitted
unlimited access to food and water at all times and were
housed under controlled environmental conditions (22
°C) with a 12 h light and 12 h dark cycle in the animal
holding facility of the Department of Molecular Biology
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and Genetics at the Bilkent University. This study protocol
complied with Bilkent University’s Local Animal Ethic
Committee (BILHADYEK) guidelines on humane care
and use of laboratory animals according to the criteria
outlined in European Convention ETS 123.
2.12. Statistical analysis
All data are expressed as means ± SD. Student’s t-test and
the Mann–Whitney U test were used with a signiﬁcance
level P < 0.05.
3. Results
3.1. Expression pattern of FLT3 in Snu398 cells
We examined the expression of FLT3 in four HCC lines.
Amongst them, Huh7 and Hep40 are well differentiated
(WD), while Snu398 and SK-Hep-1 are poorly differentiated
(PD) HCC lines (19). FLT3 expression was observed in
Snu398 cells, and to a lesser degree in Hep40 cells at the
mRNA level (Figure 1A). However, this slight expression
of FLT3 in Hep40 cells disappeared at the protein level,
and only in Snu398 cells FLT3 protein expression was
detectable (Figure 1B). Therefore, we decided to utilize
the Snu398 HCC line for in vitro experiments to test
our hypothesis. When we stably knocked-down FLT3
expression by using specific shRNA in Snu398 cells, FLT3
mRNA expression was decreased in these transfected cells
(Snu398 FLT3-shRNA) when compared with that of empty
vector transfected cells (Snu398 pGIPz) (Figure 1C). The
decrease was approximately 45% (Figure 1D). In addition,
when we performed immunofluorescence staining against
FLT3 protein, we found that in contrast to abundant
positive staining in empty vector transfected cells, few
cells express FLT3 protein in FLT3 shRNA transfected cells
(Figure 1E). In parallel to our RT-PCR data, the amount
of FLT3 expression dropped almost 50% in Snu398 FLT3shRNA transfected cells as compared with that of Snu398
pGIPz transfected cells (Figure 1F).
3.2. Functional analysis of FLT3 in Snu398 following
inhibition with K-252a and knocking-down via shRNA
transfection
In order to investigate the functional role of FLT3 in
HCC, we analyzed in vitro proliferation, migration,
and invasiveness abilities after treating with the FLT3
inhibitor K-252a or transfecting with a specific shRNA for
FLT3 in Snu398 cells. Our MTT results showed that the
proliferation ability of Snu398 cells diminished following
K-252a treatment compared to DMSO treated cells (Figure
2A) and this decrease was statically significant (P < 0.05).
Similarly there was a decrease in the proliferative capacity
of Snu398 cells when FLT3 was knocked down, albeit not
statistically significant (Figure 2B).
To assess the effect of FLT3 in the invasiveness of
Snu398 cells (Figures 2C and 2D), following K-252a
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Figure 1. Expression of FLT3 in vitro. a). FLT3 expression in well differentiated (WD) and poorly differentiated (PD) HCC cell lines at
the mRNA level. The mRNA levels are shown by RT-PCR; gapdh was used as a loading control; b) FLT3 expression in well differentiated
(WD) and poorly differentiated (PD) HCC cell lines at the protein level. The protein levels are shown by Western blot; CALNEXIN was
used as a loading control; c) expression of FLT3 mRNA in Snu398 cells transfected with shRNA against FLT3 (Snu398 FLT3-shRNA)
and in empty vector transfected cells (Snu398 pGIPz); gapdh was used as a loading control; d) quantitation of the expression of FLT3
mRNA after transfection; e) Alexa Fluor 568 labeled FLT3 protein expression in FLT3 shRNA transfected (Snu398 FLT3-shRNA) and
empty vector transfected cells (Snu398 pGIPz); nuclei were stained with DAPI; f) the percentage of the FLT3 protein expression was
calculated by dividing FLT3 positive cells by the total number of cells based on their DAPI staining both in FLT3 shRNA transfected
(Snu398 FLT3-shRNA) and empty vector transfected cells (Snu398 pGIPz).

treatment for 2 h (Figure 2C, blue lines), we observed a
diminution in the wound healing capacity of Snu398 cells
as compared with that of DMSO treated cells (Figure 2C,
red lines). We also found a similar result after transfecting
the cells with FLT3 specific shRNA (Figure 2D). FLT3
knocked-down cells’ wound healing capacity (Figure 2D,
blue lines) decreased as compared with that of empty
vector transfected control cells (Figure 2D, red lines). We
also performed a Matrigel invasion assay and compared
the number of invaded colonies (Figure 2E). Our results

showed that the invasiveness of Snu398 cells decreased
significantly after they were treated with inhibitor K-252a
or transfected with FLT3 shRNA (P < 0.05).
3.3. Role of FLT3 in the tumorigenicity and the
invasiveness of Snu398 cells in vivo
Snu398 cells were either treated with K-252a or stably
transfected by FLT3 shRNA prior to injection into the
nude mice for in vivo studies. Tumor size decreased
considerably when Snu398 cells were transplanted after
K-252a treatment (Figures 3A–3C) and FLT3 shRNA
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Figure 2. Effects of FLT3 on the in vitro proliferation, migration, and invasion ability of Snu398 cells. a) Proliferation ability of Snu398
cells after 2 h of K-252a and DMSO treatment (*: P < 0.05) by MTT assay; b) proliferation ability of Snu398 cells after transfecting
with FLT3 specific shRNA (Snu398 FLT3-shRNA) and empty vector (Snu398 pGIPz) by MTT assay; c) quantification of the effects of
K-252a treatment (blue lines) as compared with DMSO treatment (red lines) on the wound healing capacity of Snu398 cells in normal
and serum starved media; d) quantification of the effects of FLT3 specific shRNA transfected Snu398 cells (Snu398 FLT3-shRNA; blue
lines) and empty vector transfected cells (Snu398 pGIPz; red lines) on the wound healing capacity of Snu398 cells in normal and serum
starved media. The effects of FLT3 on the in vitro invasion of Snu398 cells are shown by the Matrigel assay; e) quantification of the
number of invaded colonies of Snu398 cells grown in normal medium (Snu398), control medium (Snu398 DMSO), with an inhibitor
(Snu398 K-252a), following empty vector transfection (Snu398 pGIPz) and specific FLT3 shRNA transfection (Snu398 FLT3-shRNA)
(*: P < 0.05).

transfection (Figures 3D–3F) as compared with the tumor
size of the controls. Differences in the average tumor
volumes of xenografts injected with Snu398 cells in the
presence or absence of the inhibitor were statistically
significant (P < 0.05) (Figure 3C). Snu398 cells that were
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treated with the FLT3 inhibitor (Snu398 K-252a) did not
form any measurable tumor in the area shown by the red
arrow, whereas Snu398 cells that were treated with DMSO
as a control (Snu398 DMSO) formed tumor masses in
the area shown by the blue arrow (Figure 3A). On the

AYDIN et al. / Turk J Med Sci
C

Tumor volume (mm 3)

B
15000

Snu398 DMSO
Snu398 K252a

10000
5000
0

0

14 16 20 22 24 28 31 36 40
Days

12000
Tumor volume (mm 3)

A

*

10000
8000
6000
4000
2000

A

0

RN

1 5 8 12 15 19 22 26 29 33 36 40 43
Days

2000

-F
98
Sn

u3

Sn

u3

LT

98

0

4000

sh

500

6000

3-

1000

8000

z

1500

10000

IP

2000

Snu398 pGIPz
Snu398 FLT3shRNA

G

2500

Tumor volume (mm 3)

3000

12000

-p

F

E
Tumor volume (mm 3)

D

Sn

Sn

u3
98
D

M

SO

u3
98
K25
2a

0

Figure 3. Effects of FLT3 on the in vivo tumorigenicity of Snu398 cells. a) A representative photograph of a mouse injected with
FLT3 inhibitor treated Snu398 cells (Snu398 K-252a) or with DMSO treated Snu398 cells as a control (Snu398 DMSO). Injection
sites are shown by the red and blue arrows, respectively; b) tumor growth curve of the K252-a and DMSO treated Snu398 cells; c)
the differences in the average tumor volumes of xenografts injected with Snu398 cells in the presence or absence of an inhibitor were
statistically significant (*: P < 0.05); d) a representative photograph of a mouse injected with FLT3 specific shRNA transfected Snu398
cells (Snu398-FLT3-shRNA) or with empty vector transfected Snu398 cells (Snu398-pGIPz). Injection sites are shown by red and blue
arrows, respectively; e) tumor growth curve of FLT3 shRNA and empty vector (pGIPz) transfected Snu398 cells; f) the differences in the
average tumor volumes of xenografts generated by FLT3 shRNA and control transfected Snu398 cells were not statistically significant.

other hand, the average size of the tumor formed after
injecting FLT3 shRNA transfected Snu398 (Snu398-FLT3shRNA) cells was 33% less than that of the empty vector
transfected Snu398 (Snu398-pGIPz) cells (Figure 3F), but
the difference was not statistically significant.
In addition, we examined the expression of FLT3 and
αSMA as markers for invasiveness in the xenografts with
immunofluorescence staining. We observed that very few
cells express the FLT3 protein in the tumor sections that were
generated with FLT3 shRNA transfected Snu398 (Snu398FLT3-shRNA) when compared with the sections of empty
vector transfected Snu398 (Snu398-pGIPz) cells (Figures
4A and 4B). When we quantitated the percentage of FLT3
positive cells, we found that only 10% of the cells express
the FLT3 protein in the tumors that were generated with

FLT3 shRNA transfected Snu398 (Snu398-FLT3-shRNA)
cells. On the other hand, this rate increased to 68% in the
tumors that were generated with empty vector transfected
Snu398 (Snu398-pGIPz) cells (Figure 4C). By comparing
the expression of αSMA, we also explored whether the
reduction in the tumor size reflects the less invasive nature
of FLT3 shRNA transfected Snu398 cells. Our results
showed that when FLT3 expression was knocked down,
few cells expressed αSMA (Figure 4D). However, when the
cells were transfected with the empty vector, we detected
abundant αSMA protein expression in the tumor sections as
shown by the red arrowheads (Figure 4E). αSMA expression
was seen in 25% of the cells in the FLT3 shRNA transfected
Snu398 xenograft, whereas it was 58% in the empty vector
transfected Snu398 xenograft (Figure 4F).
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Figure 4. Effects of FLT3 on the invasiveness of Snu398 cells in vivo. a) Expression of FITC labeled FLT3 protein in the section of the
tumor in nude mice generated by Snu398 cells transfected with FLT3 shRNA; merged pictures of the sections with DAPI stained nuclei
are shown on the left panel of the sections and red arrowheads denote FITC labeled FLT3 positive cells; b) expression of FITC labeled
FLT3 protein in the section of the tumor in nude mice generated by Snu398 cells transfected with pGIPz; merged pictures of the sections
with DAPI stained nuclei are shown on the left panel of the sections and red arrowheads denote FITC labeled FLT3 positive cells; c)
quantification of FLT3 positive cells with ImageJ; d) expression of FITC labeled αSMA protein in the section of the tumor in nude mice
generated by Snu398 cells transfected with FLT3 shRNA; merged pictures of the sections with DAPI stained nuclei are shown on the
left panel of the sections and red arrowheads denote FITC labeled αSMA positive cells; e) expression of FITC labeled αSMA protein in
the section of the tumor in nude mice generated by Snu398 cells transfected with pGIPz; merged pictures of the sections with DAPI
stained nuclei are shown on the left panel of the sections and red arrowheads denote FITC labeled αSMA positive cells; f) quantification
of αSMA positive cells with ImageJ.

4. Discussion
Treatment of HCC remains an urgent health concern and
there is a growing need for new therapeutic candidates. In
this study, we aimed to find a novel potential biomarker
for HCC and focused on FLT3. FLT3 is not only a marker
for hematopoietic lineage, but also a marker for hepatic
oval cells that differentiate into hepatocyte and bile duct
lineages (20,21). In addition, a close relationship between
liver development and hematopoiesis also implies that
FLT3 signaling may have a critical function in the liver
(22,23). Furthermore, we have previously shown that FLT3
may play a role in liver regeneration (10).
We analyzed the expression level of FLT3 in four HCC
cell lines. We found FLT3 protein expression only in Snu398,
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a poorly differentiated (PD) HCC line (19). Differentiation
is used in tumor grading systems and PD cancers tend
to grow and spread faster than well differentiated or
undifferentiated cancer cells. Snu398 is the only cell line
in which we detected FLT3 protein expression, suggesting
that it is more aggressive than the others. Additionally, for
the FLT3 signaling, FLT3 needs to bind its cognate ligand
(FLT3L) to transduce signals and the expression of FLT3L
in Snu398 was previously reported (24). Due to having
expressions of FLT-3 and FLT3L, we chose Snu398 cells
to explore the connection between FLT3 and HCC with in
vitro and in vivo experimental approaches.
Tyrosine kinases are key cellular targets since their
activation plays a critical role in increased cellular
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proliferation and promotion of angiogenesis and metastasis
(25,26). In fact, protein tyrosine kinase inhibitors have
been heralded as a new kind of targeted therapy and are
effective in treating a wide range of cancers (27). Thus,
we performed in vitro cell proliferation, wound healing,
and Matrigel invasion assays, and compared the results in
the presence of kinase inhibitor K-252a or in the absence
of FLT3. The cell proliferation assay was performed for
24 h in the case of K-252a treatment since this inhibitor
may lose its effectiveness in a long culture period.
However, we performed a cell proliferation assay for 72
h with shRNA transfected cells. Both inhibitor treatment
and FLT3 knock-down resulted in a diminution in the
proliferative capacity of Snu398 cells. The wound healing
assay was done under both normal medium (10% FBS)
and serum starvation (2% FBS) conditions. The reason for
investigating the behavior of Snu398 cells under serum
starvation condition was to block the proliferation of cells,
allowing only the investigation of invasiveness of cells.
Snu398 cells were treated with K-252a for 2 h after the
wounds were generated. K-252a has been shown to inhibit
kinase activity of FLT3 in a Ba/F3 cell line (28). There was
an approximate twofold decrease in the invasive capacity
of Snu398 cells following inhibitor treatment as compared
with the untreated cells. This situation was observed under
both normal and serum starvation conditions, confirming
that these findings were not due to stalled proliferation,
but to the invasiveness of Snu398 cells. Similar results were
also obtained for the invasiveness of Snu398 cells when
we knocked down the expression of FLT3 with specific
FLT3 shRNA. Wound healing capacity of empty vector
transfected cells was found to be higher as compared with
the shRNA transfected ones under both normal medium
and serum starvation conditions. As an additional
approach to investigate further the effect of inhibitor
treatment and knock-down, we performed a Matrigel
invasion assay, and again there was a reduction in the
invasive ability of inhibitor treated and shRNA transfected
Snu398 cells as compared with that of the controls.
Our in vitro data suggest a role for FLT3 in the
invasiveness of Snu398 cells. The in vitro effect of FLT3 has
been shown to act through apoptosis in other cell types. It
has been reported that FLT3 inhibition reduces Mcl-1 levels
and induces Bax activation, resulting in mitochondrial
apoptosis in acute myeloid leukemia (AML) cells (29).
Furthermore, by using a selective FLT3 inhibitor, FI-700,
they were able to enhance apoptosis in AML cells (30).
In addition, targeting PDGF-receptor and FLT3 reduced
survival and migration of human meningioma cells (31).
Further studies are required to test whether the inhibition
of FLT3 activity results in the disruption of apoptotic
pathways in HCCs.
Inhibition of FLT3 with a different type III receptor
tyrosine kinase inhibitor, MLN0518, has been shown

to suppress tumor growth in mice bearing glioma
xenografts (32). Another molecule, LY2801653, is an orally
bioavailable multikinase inhibitor with potent activity
against FLT3 and displays antitumor activities against
colon, bile duct, and lung mouse xenograft models (33). In
parallel, our results also showed that inhibiting the activity
of FLT3 has an effect on HCC. The absence of tumors in
the xenografts upon K-252a treatment provides strong
evidence that the activity of FLT3 is required for tumor
formation. It is tempting to speculate that FLT3 may also
be a marker for cancer stem cells; however, this clearly
requires new experiments to prove it. We have previously
shown that the concentration of K-252a did not have any
toxic effects (17). In addition, Snu398 cells were all viable
prior to injection, and thus we were not concerned with
K-252a’s detrimental effects on cell viability.
In addition to FLT3’s well known effect on cellular
proliferation, FLT3 may also act by regulating the
hypoxic tumor microenvironment. It is known that the
microenvironment of the tumor has an important role in
the pathogenesis and treatment of HCC since the hypoxic
tumor microenvironment contributes greatly to the extent
of tumorigenesis (34). The inhibition of the kinase activity
of FLT3 by C-1311 potently reduced the transcription of
the HIF-1-dependent reporter gene and the endogenous
HIF-1 target gene, and showed anticancer activity (35).
Therefore, it is tempting to speculate that inhibiting FLT3
either with shRNA or with specific inhibitors may reverse
the effects of hypoxia in HCC and additional experiments
are warranted to test this.
We also showed for the first time that the inhibition
of the activity of FLT3 coincided with the reduction in
αSMA positive cells in xenografts, suggesting FLT3’s
possible involvement during in vivo invasiveness. αSMA
is a marker for epithelial mesenchymal transition (EMT),
which has been shown to play a very important role in
tumor invasiveness and normal developmental processes
(36). The induction of EMT has been documented in the
metastasis of many cancers, including HCC (37). Downregulation of αSMA expressing cells after transfecting
Snu398 cells with shRNA suggests a possible role for FLT3
during metastasis. However, the molecular mechanism of
this effect remains to be resolved.
Finally, targeting a specific kinase instead of a group
of kinases may also be useful in decreasing the side effects
during therapy. One of the promising drugs currently
used for advanced and intermediate HCC is sorafenib
(Nexavar) (38). Sorafenib is a multikinase inhibitor with
activity against RAF kinases and several receptor tyrosine
kinases, including vascular endothelial growth factor
receptor (VEGFR), platelet-derived growth factor receptor
(PDGFR), FLT3, Ret, and c-Kit (39,40). Drug-related
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adverse events in patients receiving sorafenib therapy
include diarrhea and hand/foot skin reactions, and they
may cause the discontinuation of treatment (41,42). The
inhibition of VEGFR and PDGFR has been thought to be
responsible for this effect (41,42). Therefore, to interfere
only with the kinase activity of FLT3 may also be a useful
approach to avoid the unwanted effects during therapy.
When all our findings are examined, a connection
between FLT3 and HCC can be drawn. From the work
described in this article we were able to show that the
inhibition of FLT3 either by using an inhibitor for its kinase
activity or after a stable knock-down with a specific shRNA,

resulted in the diminution of proliferation, migration, and
tumor forming abilities of HCCs both in vitro and in vivo.
Therefore, in addition to acute myelogenous leukemia,
FLT3 may also be a good therapeutic target in HCC
treatment due to the impairment in tumor forming ability
of HCC cells following the blockage of FLT3 activity.
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